ZA200007811B - Methods for amyloid removal using anti-amyloid antibodies. - Google Patents

Methods for amyloid removal using anti-amyloid antibodies. Download PDF

Info

Publication number: ZA200007811B
Authority: ZA; South Africa
Prior art keywords: fragment; composition; substance; immunoglobulin; amyloid
Prior art date: 1998-05-21

Application number

ZA200007811A

Other languages

English (en)

Inventor

Alan Solomon

Rudi Wall Jonathan S Hrncic

Original Assignee

Univ Tennessee Res Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-21

Filing date

2000-12-21

Publication date

2002-06-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22196938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200007811(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-12-21 Application filed by Univ Tennessee Res Corp filed Critical Univ Tennessee Res Corp

2002-06-21 Publication of ZA200007811B publication Critical patent/ZA200007811B/en

Links

238000000034 method Methods 0.000 title claims abstract description 96
108060003951 Immunoglobulin Proteins 0.000 claims abstract description 128
102000018358 immunoglobulin Human genes 0.000 claims abstract description 128
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 106
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 103
239000012634 fragment Substances 0.000 claims abstract description 78
102000001049 Amyloid Human genes 0.000 claims abstract description 46
108010094108 Amyloid Proteins 0.000 claims abstract description 46
229920001184 polypeptide Polymers 0.000 claims description 97
241000282414 Homo sapiens Species 0.000 claims description 61
239000000203 mixture Substances 0.000 claims description 57
239000000126 substance Substances 0.000 claims description 48
238000011282 treatment Methods 0.000 claims description 36
108090000623 proteins and genes Proteins 0.000 claims description 31
150000007523 nucleic acids Chemical class 0.000 claims description 24
208000037259 Amyloid Plaque Diseases 0.000 claims description 22
102000004169 proteins and genes Human genes 0.000 claims description 22
108020004707 nucleic acids Proteins 0.000 claims description 19
102000039446 nucleic acids Human genes 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 13
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
239000002243 precursor Substances 0.000 claims description 13
238000002360 preparation method Methods 0.000 claims description 9
238000004519 manufacturing process Methods 0.000 claims description 8
102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 6
108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 3
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
230000009257 reactivity Effects 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims 12
-1 F(ab’) Substances 0.000 claims 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 2
230000003941 amyloidogenesis Effects 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 2
108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
230000024932 T cell mediated immunity Effects 0.000 claims 1
238000012258 culturing Methods 0.000 claims 1
239000000463 material Substances 0.000 abstract description 10
230000003571 opsonizing effect Effects 0.000 abstract description 4
230000021633 leukocyte mediated immunity Effects 0.000 abstract 1
206010002022 amyloidosis Diseases 0.000 description 28
210000004027 cell Anatomy 0.000 description 26
241000699666 Mus <mouse, genus> Species 0.000 description 21
206010059047 Amyloidoma Diseases 0.000 description 15
241001465754 Metazoa Species 0.000 description 15
108010047041 Complementarity Determining Regions Proteins 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
229940072221 immunoglobulins Drugs 0.000 description 11
206010002023 Amyloidoses Diseases 0.000 description 10
108700005091 Immunoglobulin Genes Proteins 0.000 description 10
241000699670 Mus sp. Species 0.000 description 10
239000000427 antigen Substances 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
239000000523 sample Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
239000013598 vector Substances 0.000 description 8
238000000338 in vitro Methods 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
238000002965 ELISA Methods 0.000 description 6
241000894007 species Species 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
230000008021 deposition Effects 0.000 description 5
238000009396 hybridization Methods 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
108020004414 DNA Proteins 0.000 description 4
108091028043 Nucleic acid sequence Proteins 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
210000000440 neutrophil Anatomy 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
102100025390 Integrin beta-2 Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
208000024777 Prion disease Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
210000003719 b-lymphocyte Anatomy 0.000 description 3
230000008499 blood brain barrier function Effects 0.000 description 3
210000001218 blood-brain barrier Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000002649 immunization Methods 0.000 description 3
239000002596 immunotoxin Substances 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
235000002639 sodium chloride Nutrition 0.000 description 3
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
208000023761 AL amyloidosis Diseases 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
206010008111 Cerebral haemorrhage Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
206010036673 Primary amyloidosis Diseases 0.000 description 2
108091000054 Prion Proteins 0.000 description 2
102000029797 Prion Human genes 0.000 description 2
241000700159 Rattus Species 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
239000000284 extract Substances 0.000 description 2
230000035557 fibrillogenesis Effects 0.000 description 2
108020001507 fusion proteins Proteins 0.000 description 2
102000037865 fusion proteins Human genes 0.000 description 2
238000000227 grinding Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
238000003364 immunohistochemistry Methods 0.000 description 2
230000002637 immunotoxin Effects 0.000 description 2
231100000608 immunotoxin Toxicity 0.000 description 2
229940051026 immunotoxin Drugs 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000002823 phage display Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
238000010186 staining Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000014723 transformation of host cell by virus Effects 0.000 description 2
210000000689 upper leg Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
241001585273 Apantesis arge Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
201000010374 Down Syndrome Diseases 0.000 description 1
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010016202 Familial Amyloidosis Diseases 0.000 description 1
206010016207 Familial Mediterranean fever Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
241000283953 Lagomorpha Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
SZRPVOFXFLWAPX-UHFFFAOYSA-K P(=O)([O-])([O-])O.[Ca+2].[Cl-].[Rb+] Chemical compound P(=O)([O-])([O-])O.[Ca+2].[Cl-].[Rb+] SZRPVOFXFLWAPX-UHFFFAOYSA-K 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000002774 Paraproteinemias Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
206010036105 Polyneuropathy Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
208000008116 Traumatic Cerebral Hemorrhage Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000003302 anti-idiotype Effects 0.000 description 1
238000011091 antibody purification Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000019069 chronic childhood arthritis Diseases 0.000 description 1
230000010405 clearance mechanism Effects 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
229960001338 colchicine Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000000568 immunophagocytic effect Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
206010022498 insulinoma Diseases 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
238000002955 isolation Methods 0.000 description 1
201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 1
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
201000002266 mite infestation Diseases 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
208000010626 plasma cell neoplasm Diseases 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
230000007824 polyneuropathy Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000001991 scapula Anatomy 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229940002004 the magic bullet Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011426 transformation method Methods 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Genetics & Genomics (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ZA200007811A 1998-05-21 2000-12-21 Methods for amyloid removal using anti-amyloid antibodies. ZA200007811B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8619898P	1998-05-21	1998-05-21

Publications (1)

Publication Number	Publication Date
ZA200007811B true ZA200007811B (en)	2002-06-21

Family

ID=22196938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200007811A ZA200007811B (en)	1998-05-21	2000-12-21	Methods for amyloid removal using anti-amyloid antibodies.

Country Status (17)

Country	Link
EP (1)	EP1078005B1 (ko)
JP (2)	JP2002515235A (ko)
KR (1)	KR100701580B1 (ko)
CN (2)	CN1344275A (ko)
AT (1)	ATE465178T1 (ko)
AU (1)	AU4007599A (ko)
CA (1)	CA2325600A1 (ko)
DE (1)	DE69942274D1 (ko)
DK (1)	DK1078005T3 (ko)
ES (1)	ES2345746T3 (ko)
IL (1)	IL139095A0 (ko)
MX (1)	MXPA00011348A (ko)
NZ (1)	NZ507727A (ko)
PT (1)	PT1078005E (ko)
RU (1)	RU2004107695A (ko)
WO (1)	WO1999060024A1 (ko)
ZA (1)	ZA200007811B (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1072897A (en)	1995-12-12	1997-07-03	Karolinska Innovations Ab	Peptide binding the klvff-sequence of amyloid beta
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) *	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US7060670B1 (en)	1999-05-05	2006-06-13	Neurochem (International) Limited	Stereoselective antifibrillogenic peptides and peptidomimetics thereof
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
PT1257584E (pt)	2000-02-24	2005-01-31	Lilly Co Eli	Anticorpos humanizados que sequestram peptido beta-amiloide
AU2001253158A1 (en)	2000-04-05	2001-10-23	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
ES2312569T3 (es)	2001-04-30	2009-03-01	Eli Lilly And Company	Anticuerpos humanizados.
AU2002258808A1 (en)	2001-04-30	2002-11-11	Eli Lilly And Company	Humanized antibodies
PT1944040E (pt)	2001-08-17	2012-10-31	Univ Washington	Método de avaliação para a doença de alzheimer
EP1820806A1 (en) *	2006-02-16	2007-08-22	Crossbeta Biosciences B.V.	Affinity regions
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
RU2353389C2 (ru) *	2002-10-09	2009-04-27	Ринат Ньюросайенс Корп.	Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций
CA2501945A1 (en) *	2002-10-09	2004-04-22	Rinat Neuroscience Corp.	Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en)	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8697082B2 (en)	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US7575747B2 (en)	2003-02-10	2009-08-18	Applied Molecular Evolution	Aβ binding molecules
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
TWI374893B (en)	2003-05-30	2012-10-21	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7674599B2 (en)	2003-11-08	2010-03-09	Elan Pharmaceuticals, Inc.	Methods of using antibodies to detect alpha-synuclein in fluid samples
TW200636066A (en)	2004-12-15	2006-10-16	Elan Pharm Inc	Humanized antibodies that recognize beta amyloid peptide
CA2590337C (en)	2004-12-15	2017-07-11	Neuralab Limited	Humanized amyloid beta antibodies for use in improving cognition
UA95933C2 (ru) *	2005-11-30	2011-09-26	Эбботт Леборетриз	АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Ab (20-42), ИХ АНТИГЕНСВЯЗУЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, КОТОРЫЕ СОДЕРЖАТ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЕ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
SI2842967T1 (sl)	2007-01-18	2017-01-31	Eli Lilly And Company	Pegilirani amiloid beta fab
DK3067066T3 (da)	2007-02-23	2019-05-20	Prothena Biosciences Ltd	Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
AU2008220785B2 (en)	2007-03-01	2013-02-21	Vivoryon Therapeutics N.V.	New use of glutaminyl cyclase inhibitors
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
EP2142514B1 (en)	2007-04-18	2014-12-24	Probiodrug AG	Thiourea derivatives as glutaminyl cyclase inhibitors
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2106802A1 (en)	2008-04-02	2009-10-07	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Modified peptides as synthetic vaccines in amyloid-associated disease
AT509611B1 (de) *	2008-06-12	2012-04-15	Affiris Forschungs-Und Entwicklungs Gmbh	Vakzin
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
DK2475428T3 (en)	2009-09-11	2015-09-28	Probiodrug Ag	Heterocyclic derivatives as glutaminylcyklaseinhibitorer
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
BR112012022478B1 (pt)	2010-03-10	2021-09-21	Probiodrug Ag	Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US9683017B2 (en)	2014-07-17	2017-06-20	University Tennessee Research Foundation	Inhibitory peptides of viral infection
JP2017528449A (ja)	2014-08-26	2017-09-28	ユニバーシティオブテネシーリサーチファウンデーション	アミロイドーシスのための標的化免疫療法
GB201708262D0 (en) *	2017-05-23	2017-07-05	Binding Site Group Ltd	Assay for plasma cell associated disease
CA3067597C (en) *	2017-06-29	2023-03-21	The Trustees Of Columbia University In The City Of New York	Chimeric antibodies for treatment of amyloid deposition diseases
US11382974B2 (en)	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
EP3461819B1 (en)	2017-09-29	2020-05-27	Probiodrug AG	Inhibitors of glutaminyl cyclase
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
MX2022005850A (es) *	2019-11-15	2022-08-15	Univ Tennessee Res Found	Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
AU2022277951A1 (en)	2021-05-18	2023-11-16	Attralus, Inc.	Antibody-peptide fusion proteins for treating amyloid disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5004697A (en) *	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

1999
- 1999-05-21 CN CN99808844A patent/CN1344275A/zh active Pending
- 1999-05-21 NZ NZ507727A patent/NZ507727A/en active IP Right Revival
- 1999-05-21 KR KR1020007013040A patent/KR100701580B1/ko not_active Expired - Fee Related
- 1999-05-21 IL IL13909599A patent/IL139095A0/xx unknown
- 1999-05-21 MX MXPA00011348A patent/MXPA00011348A/es active IP Right Grant
- 1999-05-21 PT PT99923260T patent/PT1078005E/pt unknown
- 1999-05-21 AT AT99923260T patent/ATE465178T1/de not_active IP Right Cessation
- 1999-05-21 WO PCT/US1999/011200 patent/WO1999060024A1/en active IP Right Grant
- 1999-05-21 ES ES99923260T patent/ES2345746T3/es not_active Expired - Lifetime
- 1999-05-21 DE DE69942274T patent/DE69942274D1/de not_active Expired - Lifetime
- 1999-05-21 AU AU40075/99A patent/AU4007599A/en not_active Abandoned
- 1999-05-21 CA CA002325600A patent/CA2325600A1/en not_active Abandoned
- 1999-05-21 DK DK99923260.6T patent/DK1078005T3/da active
- 1999-05-21 JP JP2000549642A patent/JP2002515235A/ja active Pending
- 1999-05-21 EP EP99923260A patent/EP1078005B1/en not_active Revoked
- 1999-05-21 CN CNA2004100636511A patent/CN1589903A/zh active Pending
2000
- 2000-12-21 ZA ZA200007811A patent/ZA200007811B/en unknown
2004
- 2004-03-15 RU RU2004107695/14A patent/RU2004107695A/ru not_active Application Discontinuation
2010
- 2010-03-24 JP JP2010068108A patent/JP2010159284A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN1589903A (zh)	2005-03-09
RU2004107695A (ru)	2005-08-27
KR20010052374A (ko)	2001-06-25
IL139095A0 (en)	2001-11-25
KR100701580B1 (ko)	2007-03-30
HK1035542A1 (en)	2001-11-30
AU4007599A (en)	1999-12-06
DE69942274D1 (de)	2010-06-02
DK1078005T3 (da)	2010-08-09
ES2345746T3 (es)	2010-09-30
EP1078005A1 (en)	2001-02-28
CA2325600A1 (en)	1999-11-25
EP1078005B1 (en)	2010-04-21
PT1078005E (pt)	2010-08-30
NZ507727A (en)	2003-11-28
MXPA00011348A (es)	2003-04-22
ATE465178T1 (de)	2010-05-15
WO1999060024A9 (en)	2000-02-10
JP2002515235A (ja)	2002-05-28
CN1344275A (zh)	2002-04-10
JP2010159284A (ja)	2010-07-22
WO1999060024A1 (en)	1999-11-25

Publication	Publication Date	Title
US8105594B2 (en)	2012-01-31	Methods for amyloid removal using anti-amyloid antibodies
EP1078005B1 (en)	2010-04-21	Methods for amyloid removal using anti-amyloid antibodies
CN110582511B (zh)	2023-08-08	抗N3pGlu淀粉状蛋白β肽抗体及其用途
EP0805871B2 (en)	2006-02-22	Anti-cd30 antibodies preventing proteolytic cleavage and release of membrane-bound cd30 antigen
KR100767146B1 (ko)	2007-10-15	Ａβ 펩티드를 격리시키는 인간화 항체
EP2430051B1 (en)	2016-03-23	Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
EP1018518A2 (en)	2000-07-12	Use of autoantibodies for tumor therapy and prophylaxis
JP2025011153A (ja)	2025-01-23	Ｃｌｄｎ１８．２抗体及びその使用
AU2003262458B2 (en)	2008-06-19	Methods for amyloid removal using anti-amyloid antibodies
JP4044733B2 (ja)	2008-02-06	ベロ毒素ｉｉを認識するヒト型化抗体、および該抗体を産生する細胞株
HK1035542B (en)	2010-12-24	Methods for amyloid removal using anti-amyloid antibodies
US20030180799A1 (en)	2003-09-25	Antibodies against plasma cells
CA3091711A1 (en)	2019-08-29	Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders
JP2004532626A (ja)	2004-10-28	二重特異性分子のポリクローナル集団、ならびにそれらの産生方法および使用
CN116333145B (zh)	2023-11-07	结合活化凝血因子ix的抗体
OA20246A (en)	2022-03-18	Monoclonal antibodies against the beta chain region of human TRBV9.
WO2004020574A2 (en)	2004-03-11	Scfv fragment to human cathepsin l and methods of use
CN118146369A (zh)	2024-06-07	一种抗人与鼠TfR的抗体或其抗原结合片段及其用途
HK40005250A (en)	2020-05-08	Compositions and methods for treating spinal muscular atrophy
HK1196570B (en)	2017-01-06	Anti a beta antibody formulation
KR20160084177A (ko)	2016-07-13	뮤턴트 루테리알에 특이적으로 결합하는 항체 및 이의 제조방법